Sorafenib and Thyroid Cancer
作者： Poupak Fallahi , Silvia Martina Ferrari , Francesca Santini , Alda Corrado , Gabriele Materazzi
DOI: 10.1007/S40259-013-0049-Y
关键词:
摘要: Sorafenib (Nexavar) is a multikinase inhibitor, which has demonstrated both anti-proliferative and anti-angiogenic properties in vitro vivo, inhibiting the activity of targets present tumor cell [c-RAF (proto-oncogene serine/threonine-protein kinase), BRAF, V600EBRAF, c-KIT, FMS-like tyrosine kinase 3] vessels (c-RAF, vascular endothelial growth factor receptor-2, receptor-3, platelet-derived receptor β). For several years, sorafenib been approved for treatment hepatocellular carcinoma advanced renal carcinoma. After previous studies showing that was able to inhibit oncogenic RET mutants, angiogenesis orthotopic anaplastic thyroid cancer xenografts nude mice, some clinical trials effectiveness cancer. Currently, evaluation safety efficacy ongoing. This article reviews anti-neoplastic effect Several completed (or ongoing) have evaluated long-term tolerability patients with papillary medullary aggressive The results suggest promising therapeutic option not responsive traditional strategies.
springer.com
core.ac.uk
sci-hub.se 参考文章(83)
D Wynford-Thomas, F S Wyllie, N R Lemoine, E D Williams, B Stringer, E S Mayall, M Goyns, High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene. ,vol. 4, pp. 159- 164 ,(1989)
Kevin E. Bove, Yuri E. Nikiforov, James A. Fagin, Hector Monforte-Munoz, Jon M. Rowland, Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Research. ,vol. 57, pp. 1690- 1694 ,(1997)
J. Bready, A. Polverino, J. Canon, R. Kendall, T. Osgood, A. Coxon, R. Radinsky, L. Wang, P. Hughes, J. Estrada, S. Kaufman, Anti-tumor activity of motesanib in a medullary thyroid cancer model. Journal of Endocrinological Investigation. ,vol. 35, pp. 181- 190 ,(2012) , 10.3275/7609
Pallavi Iyer, Jennifer L.R. Mayer, Jeffrey M. Ewig, Response to sorafenib in a pediatric patient with papillary thyroid carcinoma with diffuse nodular pulmonary disease requiring mechanical ventilation. Thyroid. ,vol. 24, pp. 169- 174 ,(2014) , 10.1089/THY.2012.0468
A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu, M. J. Thun, Cancer statistics, 2007. CA: A Cancer Journal for Clinicians. ,vol. 57, pp. 43- 66 ,(2007) , 10.3322/CANJCLIN.57.1.43
Jonas Anders, Svend Kjær, Carlos F. Ibáñez, Molecular Modeling of the Extracellular Domain of the RET Receptor Tyrosine Kinase Reveals Multiple Cadherin-like Domains and a Calcium-binding Site Journal of Biological Chemistry. ,vol. 276, pp. 35808- 35817 ,(2001) , 10.1074/JBC.M104968200
Alessandro Antonelli, Paolo Miccoli, Victor E. Derzhitski, G. Panasiuk, Natalia Solovieva, Lidio Baschieri, Epidemiologic and clinical evaluation of thyroid cancer in children from the Gomel region (Belarus) World Journal of Surgery. ,vol. 20, pp. 867- 871 ,(1996) , 10.1007/S002689900132
J-M Lee, G A Sarosy, C M Annunziata, N Azad, L Minasian, H Kotz, J Squires, N Houston, E C Kohn, Combination therapy: Intermittent sorafenib with bevacizumab yields activity and decreased toxicity British Journal of Cancer. ,vol. 102, pp. 495- 499 ,(2010) , 10.1038/SJ.BJC.6605514
Bryan R. Haugen, Management of the patient with progressive radioiodine non-responsive disease Seminars in Surgical Oncology. ,vol. 16, pp. 34- 41 ,(1999) , 10.1002/(SICI)1098-2388(199901/02)16:1<34::AID-SSU7>3.0.CO;2-2
Stephanie M. Cohen, Ridhwi Mukerji, Barbara N. Timmermann, Abbas K. Samadi, Mark S. Cohen, A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers American Journal of Surgery. ,vol. 204, pp. 895- 901 ,(2012) , 10.1016/J.AMJSURG.2012.07.027